Cite
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk undergoing allogeneic stem cell transplantation in CR
MLA
Klyuchnikov, Evgeny, et al. “Individualized Busulfan Dosing Improves Outcomes Compared to Fixed‐dose Administration in Pre‐transplant Minimal Residual Disease‐positive Acute Myeloid Leukemia Patients with Intermediate‐risk Undergoing Allogeneic Stem Cell Transplantation in CR.” European Journal of Haematology, vol. 110, no. 2, Feb. 2023, pp. 188–97. EBSCOhost, https://doi.org/10.1111/ejh.13893.
APA
Klyuchnikov, E., Langebrake, C., Badbaran, A., Dadkhah, A., Massoud, R., Freiberger, P., Ayuk, F., Janson, D., Wolschke, C., Bacher, U., & Kröger, N. (2023). Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk undergoing allogeneic stem cell transplantation in CR. European Journal of Haematology, 110(2), 188–197. https://doi.org/10.1111/ejh.13893
Chicago
Klyuchnikov, Evgeny, Claudia Langebrake, Anita Badbaran, Adrin Dadkhah, Radwan Massoud, Petra Freiberger, Francis Ayuk, et al. 2023. “Individualized Busulfan Dosing Improves Outcomes Compared to Fixed‐dose Administration in Pre‐transplant Minimal Residual Disease‐positive Acute Myeloid Leukemia Patients with Intermediate‐risk Undergoing Allogeneic Stem Cell Transplantation in CR.” European Journal of Haematology 110 (2): 188–97. doi:10.1111/ejh.13893.